**EuroNanoMed**

**Joint Transnational Call for Proposals (JTC2020) for**

**“European Innovative Research & Technological Development Projects in Nanomedicine”**

**Guidelines for Applicants**

**DEADLINES**

**January 21st 2020 (17:00, CET) - SUBMISSION OF PRE-PROPOSALS**

**June 10th 2020 (17:00, CEST) - SUBMISSION OF INVITED FULL-PROPOSALS**

\_\_\_\_\_\_\_\_\_

https://ptoutline.eu/app/euronanomed2020

(The submission system will be open by December 2nd, 2019)

**EuroNanoMed III Joint Call Secretariat**

JCS is hosted by the French National Research Agency

50 avenue Daumesnil

75012 Paris

Martine BATOUX & Marie-Pierre GOSSELIN

[ENMCalls@agencerecherche.fr](mailto:ENMCalls@agencerecherche.fr)

Tel. +33 (0)1 73 54 81 40

Tel. +33 (0)1 78 09 80 38

[www.euronanomed.net](http://www.euronanomed.net)

Table of content

[Background 3](#_Toc23412222)

[Registration 3](#_Toc23412223)

[Building your proposal 3](#_Toc23412224)

[Proposal submission 4](#_Toc23412225)

[Annex 1: Contact Point list 7](#_Toc23412226)

[Annex 2: INFORMATION FOR APPLICANTS NATIONAL ELIGIBILITY CRITERIA 8](#_Toc23412227)

[BELGIUM (French speaking community) 8](#_Toc23412228)

[BULGARIA 9](#_Toc23412229)

[CANADA (Québec) 10](#_Toc23412230)

[CZECH REPUBLIC 12](#_Toc23412231)

[EGYPT 17](#_Toc23412232)

[ESTONIA 19](#_Toc23412233)

[FRANCE 20](#_Toc23412234)

[GREECE 22](#_Toc23412235)

[ISRAEL 26](#_Toc23412236)

[ITALY 28](#_Toc23412237)

[LATVIA 31](#_Toc23412238)

[LITHUANIA 33](#_Toc23412239)

[NORWAY 35](#_Toc23412240)

[POLAND 38](#_Toc23412241)

[ROMANIA 41](#_Toc23412242)

[SLOVAKIA 43](#_Toc23412243)

[SPAIN (CDTI) 45](#_Toc23412244)

[SPAIN (ISCIII) 48](#_Toc23412245)

[SPAIN (AEI) 52](#_Toc23412246)

[TAIWAN 55](#_Toc23412247)

[TURKEY 56](#_Toc23412248)

[Annex 3: Technology readiness levels (TRL) 60](#_Toc23412249)

[Annex 4: Guidelines for Responsible Research and Innovation (RRI) in proposals to EuroNanoMed III 61](#_Toc23412250)

Background

Under the umbrella of EuroNanoMed III (ERA-NET Cofund for research programmes on nanomedicine), 21 funding organisations have agreed to launch the 11th Joint Transnational Call for collaborative innovative research projects in nanomedicine. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. Please read the Call text for further details.

Registration

Research project consortia who intend to submit a transnational proposal should register at [https://ptoutline.eu/app/euronanomed2020](https://antiphishing.vadesecure.com/2/TWFyaWUtUGllcnJlLkdPU1NFTElOQGFnZW5jZXJlY2hlcmNoZS5mcnxWUkM4MDQ0MzI%3D/ptoutline.eu/app/euronanomed2020), clicking the “sign up” button and following the directions. The system will be opened by December 2, 2019. To register, please complete the different sections as soon as possible.

Building your proposal

Please find a few references that could be helpful:

* Look at the Nanomedicine Map on ETPN website to find potential partners: <http://www.etp-nanomedicine.eu/public/public/european-nanomedicine-map>
* **Please check if you are included in the map.** You could easily include your group and contact details to be found by consortia in preparation.
* Use the EuroNanoMed partnering tool (<http://www.euronanomed.net/partner-search/list-of-searches-and-offers/>)
* Facilities and services at European level that you could contact:
  + - The nanocharacterization lab EU-NCL: <http://www.euncl.eu/>
    - The nanomedicine pilots funded by EU:
      * Nanofacturing is a multiple-scale, manufacturing platform to support the extensive pipeline of nanopharmaceutical products being developed in Europe: <http://nanofacturing.eu/>
      * Nanopilot project, a Pilot Plant for the Production of Polymer-based Nanopharmaceuticals in Compliance with Good Manufacturing Practices (GMP): <http://www.nanopilot.eu/>
      * Enabling Nanomedicine Translation: <http://www.enatrans.eu/>
    - European Research Infrastructures:
      * Clinical Research Infrastructure Network (ECRIN): <http://www.ecrin.org/>
      * European Infrastructure for Translational Medicine (EATRIS): [www.eatris.eu](http://www.eatris.eu)
      * Biobanking and Biomolecular Resources Research Infrastructure (BBMRI): <http://bbmri-eric.eu/about>
      * The European Life Sciences Infrastructure for Biological Information (ELIXIR): <http://www.elixir-europe.org/> and <https://www.elixir-europe.org/personalised-medicine>
      * European Infrastructure for Phenotyping, Archiving and Distribution of Mouse Models (INFRAFRONTIER): <https://www.infrafrontier.eu/>
* Please visit the **Responsible Research and Innovation** sites:
  + - EuroNanoMed3 website v2.0 of the RRI Guidelines:   
      <http://euronanomed.net/joint-calls/enmiii-rri-guidelines/>
    - and of the EU: <https://ec.europa.eu/programmes/horizon2020/en/h2020-section/responsible-research-innovation>
    - Public engagement, open access, gender equality, science education, ethics and good governance should be taken into account.
    - The EU NanoSafety Cluster: <http://www.nanosafetycluster.eu/>
    - The Enterprise Europe Network: https://een.ec.europa.eu/
    - of the EU: <https://ec.europa.eu/programmes/horizon2020/en/h2020-section/responsible-research-innovation>
    - and EuroNanoMed website: <http://www.euronanomed.net/joint-calls/enm-rri-guidelines/>
* Helpdesk for Intellectual Property Rights issues: <https://www.iprhelpdesk.eu/>
* Guidelines on FAIR Data Management in Horizon 2020: <http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-data-mgt_en.pdf>

Proposal submission

|  |
| --- |
| Please read carefully the Call Text and the relevant central and national/regional eligibility and budgetary criteria (see Annexes) before starting your proposal in order to check if you fulfil the call’s formal requirements. |

There will be a two-steps submission and evaluation procedure for joint applications: pre-proposals and full proposals. In both cases, one joint proposal document (in English) shall be prepared by the partners of a joint transnational proposal, and must be submitted by one spokesperson, the coordinator, to the JCS by uploading it on the electronic submission system:

[https://ptoutline.eu/app/euronanomed2020](https://antiphishing.vadesecure.com/2/TWFyaWUtUGllcnJlLkdPU1NFTElOQGFnZW5jZXJlY2hlcmNoZS5mcnxWUkM4MDQ0MzI%3D/ptoutline.eu/app/euronanomed2020)

The electronic submission system will be available from December 2nd, 2019.

Please use the proposal templates (for pre- and full proposals) provided on the EuroNanoMed website ([www.euronanomed.net](file:///\\Si0036v\Recherche\_Direction%20Internationale\Programmes\EuroNanoMed\3.%20Appels\JTC%202014\AppData\Local\Microsoft\Windows\Temporary%20Internet%20Files\Content.Outlook\JLN99GMK\www.euronanomed.net)) and complete all fields and respect the format of each section. Only the proposal template will be accepted. Please keep in mind that the templates have a fixed maximum size. Thus, the proposal document cannot be longer than the number of pages indicated in the proposal templates (DIN-A4, Calibri 11, single-spaced). In addition, the proposal in a digitally signed PDF-Format file (with a scanned version of the original signature page) to be uploaded to the online tool must not exceed 8 Megabytes. Proposals exceeding these limitations will be rejected by the online system.

Deadline to submit pre-proposals: **January 21st, 2020 (17:00, CET)**

Deadline to submit full proposals: **June 10th, 2020 (17:00, CEST)**

After these deadlines, the server will not accept proposals and it will not be possible to amend the proposal or to add further documents.

Please take into account that the online data entry may be overloaded by the day of the deadline. It is therefore recommended to complete the registration and upload the proposal in proper time.

In case of inconsistencies between the information registered in the submission tool and the information included in the PDF of this application form, the information registered in the submission tool shall prevail.

For applicants from some countries/regions it might be also necessary to submit the proposal and/or other information, in some cases before the deadline of this call, directly to the relevant national/regional funding organisations. Therefore, applicants are strongly advised to check their respective country/region funding organisation eligibility and other specific information (see tables below). For more details, applicants may also get in touch with the respective funding organisations Contact Persons (see below). For central and additional information, you can contact the Joint Call Secretariat (JCS) at:

National Research Agency (ANR)

Martine BATOUX & Marie-Pierre GOSSELIN

[ENMCalls@anr.fr](mailto:ENMCalls@anr.fr)

Tel. +33 (0)1 73 54 81 40

Tel. +33 (0)1 78 09 80 38

|  |
| --- |
| **Please Note**:  It is mandatory to meet the deadline and the format of the proposal structure. The Joint Call Secretariat will check the proposals submitted to ensure that they meet the call’s formal criteria (e.g. date of submission; number of participating member states, category of project partners (academic, clinical/public health and industrial/SMEs), inclusion of all necessary information in English and appropriate limits on length). In parallel, the Joint Call Secretariat will forward the proposals to the relevant national/regional funding organisations that will perform a formal check of compliance with their respective eligibility criteria. Proposals not meeting the formal central and /or national/regional eligibility criteria will be rejected. Proposals passing both checks will be forwarded to independent international scientific experts for evaluation.  Potential project consortium coordinators are recommended to read the EuroNanoMed funding organisations’ eligibility criteria when they are looking for potential project consortium partners.  Project partners are strongly advised to read the specific eligibility criteria of the relevant funding organisations and other requirements and to contact their respective Contact Persons prior to submitting the application (see "Contact Point List" and "Information for Applicants" below). |

Annex 1: Contact Point list

|  |  |  |  |
| --- | --- | --- | --- |
| Country | Funding Organisation | Contact point | Email |
| **Belgium** | FRS-FNRS | Joël Groeneveld | joel.groeneveld@frs-fnrs.be |
| **Bulgaria** | BNSF | Milena Aleksandrova | aleksandrova@mon.bg |
| **Canada (Québec)** | FRQS | Maxime Beaudoin | [Maxime.Beaudoin@frq.gouv.qc.ca](mailto:Maxime.Beaudoin@frq.gouv.qc.ca) |
| **Czech Republic** | TACR | Kristina Nehilčová | [kristina.nehilcova@tacr.cz](mailto:kristina.nehilcova@tacr.cz) |
| **Egypt** | ASRT | Amr Radwan | [radwan.amro@gmail.com](mailto:radwan.amro@gmail.com) |
| **Estonia** | ETAg | Aare Ignat | Aare.ignat@etag.ee |
| **France** | ANR | Martine Batoux  Marie-Pierre Gosselin | [ENMCalls@anr.fr](mailto:ENMCalls@anr.fr) |
| **Greece** | GSRT | Paraskevi Afentaki  Anna Rosenberg | [pafe@gsrt.gr](mailto:pafe@gsrt.gr)  a.rosenberg@gsrt.gr |
| **Israel** | CSO-MOH | Irit Allon  Orly Spivak | [Irit.allon@moh.gov.il](mailto:Irit.allon@moh.gov.il)  orlee.f@gmail.com |
| **Italy** | IMH | Maria Grazia Mancini | [mg.mancini-esterno@sanita.it](mailto:mg.mancini-esterno@sanita.it)  research.eu.dgric@sanita.it |
| **Latvia** | VIAA | Linda Vecbiškena | Linda.Vecbiskena@viaa.gov.lv |
| **Lithuania** | RCL | Živilė Ruželė | zivile.ruzele@lmt.lt |
| **Norway** | RCN | Cecilie A. Mathiesen | cam@rcn.no |
| **Poland** | NCBR | Marcin Chmielewski | Marcin.Chmielewski@ncbr.gov.pl |
| **Romania** | UEFISCDI | Mihaela Manole | mihaela.manole@uefiscdi.ro |
| **Slovakia** | SAS | Katarina BIBOVA | [bibova@up.upsav.sk](mailto:bibova@up.upsav.sk) |
| **Spain** | AEI | Beatriz Gomez | [beatriz.gomez@aei.gob.es](mailto:beatriz.gomez@aei.gob.es) |
| **Spain** | ISCIII | Astrid Valencia Quiñones | [ma.valencia@isciii.es](mailto:ma.valencia@isciii.es) |
| **Spain** | CDTI | Héctor González | [hector.gonzalez@cdti.es](mailto:hector.gonzalez@cdti.es) |
| **Taiwan** | MOST | Ching-Mei Tang | [cmtom@most.gov.tw](mailto:cmtom@most.gov.tw) |
| **Turkey** | TUBITAK | Alperen Erdoğan | alperen.erdogan@tubitak.gov.tr |

Annex 2: INFORMATION FOR APPLICANTS NATIONAL ELIGIBILITY CRITERIA

BELGIUM (French speaking community)

|  |  |
| --- | --- |
| Funding Organisation | Fonds de la Recherche Scientifique – FNRS (F.R.S.-FNRS) |
| Initial funding  pre-commitment | The maximum amount of requested funding per project is **200.000 EUR** for a total period of three years. If the project involves the recruitment of a PhD student, the project duration of the F.R.S.-FNRS sub-project could be up to four years. |
| National Contact Point for the 11TH call of ENM | Joël Groeneveld, Senior Policy Officer, [joel.groeneveld@frs-fnrs.be](mailto:joel.groeneveld@frs-fnrs.be), +32 2 504 9270 |
| Eligible institutions | All eligibility rules and criteria can be found in the [PINT-MULTI regulations](https://antiphishing.vadesecure.com/1/bWFyaWUtcGllcnJlLmdvc3NlbGluQGFnZW5jZXJlY2hlcmNoZS5mcnxWUkM4MDQ0MzI%3D/www.fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf). |
| Additional requirement | Applicants must provide basic administrative data by submitting an administrative application on [Semaphore](https://antiphishing.vadesecure.com/1/bWFyaWUtcGllcnJlLmdvc3NlbGluQGFnZW5jZXJlY2hlcmNoZS5mcnxWUkM4MDQ0MzI%3D/www.fnrs.be/index.php/semaphore-e-space) for the same deadline as the consortium application is submitted. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS. |
| Eligible costs | All eligibility rules and criteria can be found in the [PINT-MULTI regulations](https://antiphishing.vadesecure.com/1/bWFyaWUtcGllcnJlLmdvc3NlbGluQGFnZW5jZXJlY2hlcmNoZS5mcnxWUkM4MDQ0MzI%3D/www.fnrs.be/docs/Reglement-et-documents/International/FRS-FNRS_PINT-Multi.pdf). |
| Further guidance |  |

BULGARIA

|  |  |
| --- | --- |
| Funding Organisation | Bulgarian National Science Fund (BNSF) |
| Initial funding  pre-commitment | Up to € 230,081/450,000 BGN  Up to € 76,693/150,000 BGN per project  3 projects tentatively envisaged to be funded |
| National Contact Point for the 11TH call of ENM | Name: Milena Aleksandrova  Phone: +359 884 171 363  e-mail: milena.aleksandrova@mon.bg |
| Eligible institutions | 1) Accredited universities as defined in Art.85 para.1, p. 7 of the Higher Education Act;  2) Research organizations as defined in Art. 47, para 1 of the Higher Education Act. <http://lll.mon.bg/uploaded_files/zkn_visseto_obr_01.03.2016_EN.pdf> |
| Additional requirement | Applicants under this procedure shall be directly responsible for the implementation of the activities under the project proposal and shall not act as intermediaries, but they shall carry out activities under the project proposal on their behalf and at their expense.  Applicants to this procedure must be entities:   * Carrying out fundamental research studies; and * Whose activities are entirely of a non-profit nature; or * Whose activities are of both for-profit and not-for-profit nature, but these activities are clearly distinguished and their organization allows tracking of revenue and expenditures connected with their implementation, including by keeping analytical accounting. In the event that an applicant is involved in both for-profit and not-for-profit activities, the funding, expenditures and revenues shall be taken into account separately for each type of activity and on the basis of consistently applied principles of accounting of expenditures being justifiable. |
| Eligible costs | Eligible costs are specified in” National requirements and eligibility conditions” of Bulgarian National Science Fund available at:  <https://www.fni.bg/sites/default/files/competition/12_2016/ERA/BNSF_International_Programs-2017_ENG.pdf> |
| Further guidance | Applicants have to submit an application form for national eligibility when submitting the porposals. The formulier, entitled „Administrative description oft he project“ should be filled in both Bulgarian and in English and signed. Application forms can be obtained at:  <https://www.fni.bg/?q=node/578>  They have to be sent it back by post or in person to BNSF Registry Office before the deadline of 1stage proposal submission. |

CANADA (Québec)

|  |  |
| --- | --- |
| Funding Organisation | Fonds de recherche du Québec – Santé (FRQS); <http://www.frqs.gouv.qc.ca/> |
| Initial funding  pre-commitment | $500,000 CAD; Anticipated number of funded research groups: 1-2  Maximum allowed budget is $75,000 CAD per year for up to 3 years, per project.  *Funds are subject to availability of funds voted annually to FRQS by the National Assembly of Québec and FRQS Board of Directors’ approval.* |
| National Contact Point for the 11TH call of ENM | Maxime Beaudoin, Program Manager ([maxime.beaudoin@frq.gouv.qc.ca](mailto:maxime.beaudoin@frq.gouv.qc.ca)) |
| Eligible institutions | Quebec applicants must meet the eligibility criteria for FRQS research grants. Eligible institutions are Quebec Universities or Institutions within Quebec's health and social services network. Further information about eligibility of applicants and institutions is available in *section 2 of the* [*FRQ Common General Rules*](http://www.frqs.gouv.qc.ca/regles-generales-communes). |
| Additional requirement | **NEW:** **Quebec Principal investigator (PI)** must submit a short application form through [*FRQS electronic portfolio*](https://frqnet.frq.gouv.qc.ca/researchPortal/faces/jsp/login/login.xhtml?lang=FR&site=null).  **Quebec Co-investigator** has to consent to be part of this application before the institutional approval.  CCV of all the investigators must be updated with the most recent information for the eligibility check.  **Institutional (university)** approval must be done lastly which automatically activates the final submission.  **$CAD Budget form** will be requested only for invited PIs at the Full proposal stage through **FRQ application form.**  Once the application is submitted, it will no longer be possible to modify it.  *Transmission via the FRQS electronic portfolio only.*  Documents sent via mail or e-mail will NOT be accepted.  **FRQS short application form will follow the exact Call deadlines.** |
| Eligible costs | * Operational costs (research personnel, consumables, animals) * Remuneration of students and Scholarships * Costs related to scientific and ethical evaluation (clinical research projects) * Costs related to project coordination (project administration and travel expenses for attending joint meetings) * Costs related to knowledge translation and translation * Conference attendance (up to 5% per year of the grant amount starting the first year **with justifications**)   Further information about eligible costs is available in *section 8 of the* [*FRQ Common General Rules*](http://www.frqs.gouv.qc.ca/regles-generales-communes).  There is NO support for salaries of investigators or equipment.  Overheads means “frais indirects de recherche” and will be managed separately by the FRQS. They **should not** be included in the requested budget. |
| Further guidance | RULE FOR SELECTED PROPOSALS:  Basic research ethics training is **mandatory** for all recipients of an FRQS grant when their part of research project involve human beings. **PI and Co-PI** on the project must therefore successfully complete levels 1 and 3 of *MSSS Ethics online training* by the *Ministère de la Santé et des Services sociaux.*  Post-doctorate on the project are also encouraged to complete this training.  Ethics approval of the project will have to be sent to FRQS before the first payment of the grant.  ***Early-Career Scientist (Junior Researcher) – FRQS definition***  *Early career researchers (Junior 1 and Junior 2) are encouraged to submit an application as a Principal Investigator (the Junior status begins no more than six (6) years after obtaining a Ph.D. and lasts no more than eight (8) years). Postdoctoral trainees cannot apply to this Competition as Investigators.* |

CZECH REPUBLIC

|  |  |
| --- | --- |
| Funding Organisation | Technology Agency of the Czech Republic (TACR) |
| Initial funding  pre-commitment | € 1.000.000 |
| National Contact Point for the 11TH call of ENM | Name: Kristina Nehilčová, Project Manager  Phone: +420 234 611 629  e-mail: [kristina.nehilcova@tacr.cz](mailto:kristina.nehilcova@tacr.cz) |
| Eligible institutions | **Eligible projects for TA CR**   * the project meets the definition of applied research and innovation * the research results correspond to the national rules and are applicable / exploitable. *(The project proposal has to include a clear description of the exploitation plan and results.)* * the aim of the project has to be relevant to the overall aim of the funding [programme EPSILON](https://www.tacr.cz/wp-content/uploads/documents/2019/10/14/1571053158_Program_na_podporu_vyzkumu_vyvoje_EPSILON.pdf) * the industrial research and experimental development share corresponds to the activities of the Czech partner described in the project proposal * the applicants are eligible (based on the rules stated below) * the costs are eligible (based on the rules stated below) * the requested funding meets the national regulations for aid intensity * the applicants have published the financial statements for the years 2016, 2017, 2018   Unless the above stated conditions are met, the Czech applicant will not be considered eligible. |
| Additional requirement | Eligible applicants for TACR:  ● Enterprises (according to Annex 1 of the Regulation)  ● Research organizations (according to Article 2 paragraph 83 of the Regulation)  ● Enterprises who act as natural persons according to Annex 1 of the Regulation engaged in an economic activity pursuant to Act no. 455/1991 coll. on Trades (Trade Act).  TACR excludes the disbursement of individual aid to an enterprise:  - against which a recovery order has been issued which is unpaid  - meeting the definition of an “enterprise in difficulties” (only in Czech)  - which has not met the obligation to publish the financial statements for the years 2016, 2017, 2018 in the respective register - the so-called "Veřejný rejstřík”  Supported results  Projects that achieve at least one of the following types of results can be supported in this Call. The type of the result has to be clearly described in the project proposal:  P - patent;  G - technically realized results - prototype, functional sample;  Z - pilot plant, proven technology;  R - software;  F - results with legal protection - utility model, industrial design;  N - Certified methodologies and practices, treatment, conservation methods, procedures and specialized maps with professional expert content;  O - Miscellaneous  Results not to be recognized by the programme manager as a single result of a given project, but only in combination with at least one other result listed in the list of result types above:  H - results reflected in non-legislative directives and regulations binding within the competence of the respective provider and results reflected in the approved strategic and conceptual documents of the state or public administration. |
| Eligible costs | Budget & eligible costs  The eligible costs are:   * personnel costs (including scholarships) * subcontracting costs (max. 20% of total eligible costs throughout the whole project period) * other direct costs (write-offs, protection of intellectual property, operating expenses, travel costs, consumables) * indirect costs (overheads) - full cost/flat rate 25% (indirect costs in the respective year are calculated as 25% of the sum of the personnel costs and other direct costs in the same year.)   These specific categories of eligible costs are defined under Article 17 of [the General Terms & Conditions](https://www.tacr.cz/dokums_raw/trend/PP1/1VS/Vseobecne_podminky_v6.pdf)  Investment costs are NOT eligible in this joint call.  The costs for clinical testing (including the Phase I.) are NOT eligible. Only the costs for pre-clinical testing are eligible.  **Please note:** TA CR will fund only the topic "Diagnostics" and "Targeted delivery systems".  Funding rates  The aid intensity for each Czech applicant in the project is determined based on the type of entity according to [the Regulation](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0651) (see table below) and at the same time must not exceed the maximum permissible aid intensity for the Czech part of the project, which is 70 % of the total eligible costs.     |  |  |  |  |  | | --- | --- | --- | --- | --- | | Applicant | Industrial research | Industrial research with a bonus for effective collaboration | Experimental development | Experimental development with a bonus for effective collaboration | | Small enterprises\* | 70 % | 80 %\*\*\* | 45 % | 60 % | | Medium-sized enterprises\* | 60 % | 75 %\*\*\* | 35 % | 50 % | | Large enterprises | 50 % | 65 % | 25 % | 40 % | | Research Organisations\*\* | 100 %\*\*\* | 100 %\*\*\* | 100 %\*\*\* | 100 %\*\*\* |   \* Note: An SME is defined in Annex 1 of the Regulation  \*\* Research organisations must satisfy the definition in the Act and the Framework.  \*\*\* While respecting the maximum permissible aid intensity of 70 % per project. |
| Further guidance | Mandatory forms to be submitted  The Czech applicants are requested to submit:   * [A Sworn statement of the applicant](https://tacr.cz/dokums_raw/cofundy/cestne_prohlaseni_za_uchazece-Sworn_statement_of_the_applicant.docx); * Completed “TACR Application Form” Excel file; * if the applicant plans to achieve the “NmetS” type of result, the "[Confirmation of the Certification authority for NmetS results](https://www.tacr.cz/wp-content/uploads/documents/2019/09/27/1569580030_Formular_potvrzeni_certifikacniho_organu_NmetS.docx)" needs to be attached * if the applicant plans to achieve the “Patent” type of result, patent search must be substantiated   All documents proving the eligibility of the Czech applicant (mentioned above) shall be submitted via the TACR data box (TACR data box ID: afth9xp) within the same deadline as the project proposals. Please fill in the subject line as: „Horizon2020 - EuroNanoMed 3 Call 2020 - prokázání způsobilosti - *akronym projektu*“.  Intellectual Property Rights  The applicants are required to enter into a contract with their foreign partners (sign a so-called *Consortium Agreement*) which will define the conditions of cooperation on the project where, among other things, they specify the method of allocating rights to the research results, as well as adjustment and management of the rights imported or created during the project's implementation, which are necessary to address the project.  Useful documents and links:  - [TACR website about EuroNanoMed](https://www.tacr.cz/program/euronanomed3/)  - [programme EPSILON](https://www.tacr.cz/wp-content/uploads/documents/2019/10/14/1571053158_Program_na_podporu_vyzkumu_vyvoje_EPSILON.pdf) (only in Czech)  - [definitions of supported outcomes](https://www.tacr.cz/wp-content/uploads/documents/2019/09/27/1569575554_definice_druhu_vysledku.pdf) (only in Czech)  - Funding rules for the Czech applicant for ERA-NET cofund (available on the TACR website)  - The Guide for the Czech applicants (available on the TACR website) |

EGYPT

|  |  |
| --- | --- |
| Funding Organisation | Academy of Scientific Research and Technology, (ASRT)  Funding program: PRISM (National Program for research & innovation in biomedical sciences and health research) |
| Initial funding  pre-commitment | 0.4 Mio. €  Maximum ASRT funding for Egyptian entities Per Proposal:  1-125,000 Euro for a proposal with Egyptian partner(s) in a consortium  2-150,000 Euro If Egyptian Partner is the coordinator of the project |
| National Contact Point for the 11TH call of ENM | Dr. Amr Radwan, [Radwan.Amro@gmail.com](mailto:Radwan.Amro@gmail.com), [innov@sti.sci.eg](mailto:innov@sti.sci.eg) |
| Eligible institutions | This call is open to Egyptian legal entities established and based in Egypt. The Egyptian partner could be: research institutes, academic, non-academic organizations including NGOs and innovation agencies, industry, with special attention to small-medium size enterprises (SMEs). |
| Additional requirement | Egyptian legal entities established and based in Egypt.  Egyptian PI must not have more than two ongoing projects funded by the Academy.  The Egyptian Team must follow the National regulation for the Academy of scientific research and technology Bylaws . |
| Eligible costs | Regulations of ASRT-PRISM program applies for the eligibility of costs <http://www.asrt.sci.eg/ar/images/hea-prog.pdf>   * Eligible costs include Staff remunerations, Equipment, Publication, Consumables, kits, laboratory chemicals, materials and other relevant costs directly attributable to the project, Travel costs and Costs for professional or technical services * Total personnel costs must not exceed 25% of the total budget. * Personnel costs for public employees; (technical support staff, researcher/lecturer, assistant professor and professor) shall not exceed 4000, 6000, 7000 and 8000 Egyptian pounds, respectively. For non-public employees (i.e consultants, marketing specialists, legal experts) personnel costs can exceed the abovementioned figures and it has to be documented according to required expertise and number of working hours. * In the case of a participant participating in another ongoing publicly funded project, the allocated personnel cost in the proposal shall be decreased with 25% if participating in one additional project, 50% if participating in two other projects. In all cases, public employees at universities and research institutions can’t participate in 3 running projects. |

ESTONIA

|  |  |  |
| --- | --- | --- |
| Funding Organisation | | Eesti Teadusagentuur (Estonian Research Council)  www.etag.ee |
| Initial funding  pre-commitment | | 100.000 €  1 project tentatively envisaged to be funded. |
| National Contact Point for the 11TH call of ENM | | Dr Aare Ignat, e-mail [Aare.Ignat@etag.ee](mailto:Aare.Ignat@etag.ee)  Department of International Research Cooperation |
| Eligible institutions | | * The Host Institution must be registered and located in Estonia. R&D institutions must conform to the Organisation of Research and Development Act. For enterprises, subsection 3(2) of the Organisation of Research and Development Act does not apply. |
| Additional requirement | The Estonian Research Council (hereinafter ETAg) funds basic and applied research. Applied research is only funded as far as it does not refer to product development with commercial value and for marketing purposes. | |
| Eligible costs | | * Detailed requirements are on ETAg’s [Website](https://www.etag.ee/wp-content/uploads/2019/03/K%C3%A4skkiri-Osalusn%C3%B5uded-ERA-NET-konkurssidel-RE-rahastusega.pdf) |

FRANCE

|  |  |
| --- | --- |
| Funding Organisation | Agence Nationale de la Recherche (ANR); <http://www.agence-nationale-recherche.fr> |
| Initial funding  pre-commitment | 2.500.000 €  Anticipated number of funded research groups: ~12 |
| National Contact Point for the 11TH call of EuroNanoMed | Dr. Martine Batoux email: ENMCalls@anr.fr; Phone : +33 (0)1 73 54 81 40  Dr. Marie-Pierre Gosselin email: ENMCalls@anr.fr; Phone : +33 (0) 1 78 09 80 38  Health & Biology Department; Agence Nationale de la Recherche –ANR; 50, avenue Daumesnil - 75012 Paris,  France |
| Eligible institutions | Eligible institutions:  - Public research institutes such as EPST, EPIC, universities, university hospitals, public research institutes (max. rate of support: 100% of marginal costs).  - Enterprises: large & SMEs (max. rate of support: 45% of total costs for SMEs & 30% for larger companies). |
| Additional eligibility criteria | - The coordinator (if from a French institution) must belong to a public research organisation.  - ANR does not allow double funding and will not finance projects or parts of projects that have been funded through other ANR calls or by other funders.  ANR will cross-check the proposals submitted to ANR through the national and international calls for possible demands of double funding. |
| Eligible costs | The ANR funding regulations apply <https://www.agence-nationale-recherche.fr/RF>  Personnel, Consumables, subcontracting (up to 50% of the requested budget per partner), Small Equipment, Travel.  Please see <https://www.agence-nationale-recherche.fr/RF> for full reference.  Please note that « overheads » correspond to « frais généraux– frais d’environnement» in the ANR funding regulations, and that applicable rates vary depend on the partner’s category. Please see <http://www.agence-nationale-recherche.fr/RF> point 3.1.1.e/ for full reference. ANR has a maximum funding per partner for this call: each research team can be funded with a maximum amount of 200 000 €. There is also a minimum amount per partner: 15 000 €. |
| Further guidance | RULE FOR SELECTED PROPOSALS (if an industrial partner is involved in the project): A copy of the signed consortium agreement established between the consortium partners must be provided to ANR before the first payment of the French researchers involved in the project selected for funding.  Please see online the specific annex document for research groups applying to this call for proposals for funding in France: http://www.anr.fr/Euronanomed-2020 |

GREECE

|  |  |
| --- | --- |
| Funding Organisation | GENERAL SECRETARIAT FOR RESEARCH AND TECHNOLOGY (GSRT)  <http://www.gsrt.gr> |
| Initial funding  pre-commitment | 1.000.000 €  4-5 projects tentatively envisaged to be funded  TRL3-(8) (according to COMMISSION REGULATION (EU) No 651/2014/Definitions for Aid for Research, Development and Innovation, pages 24-26/par. 83-96)  GSRT potentially supports the following types of RTD, namely: Industrial research, experimental development, feasibility studies (COMMISSION REGULATION (EU) No 651/2014 article 25) |
| National  Programme | “***Operational Programme for Research, Entrepreneurship and Innovation 2014-2020, National Research and Innovation Strategy for Smart Specialization 2014-2020 (RIS3).*** |
| National Contact Point for the 11TH call of EuroNanoMed | Paraskevi Afentaki, [pafe@gsrt.gr](mailto:pafe@gsrt.gr), Tel. : 0030 213 13 00 112  Anna Rosenberg, [a.rosenberg@gsrt.gr](mailto:a.rosenberg@gsrt.gr), Tel. 0030 213 13 00 095 |
| Eligibility criteria and funding: | * Who can apply?   GSRT potentially supports all private and public legal entities namely: private enterprises (such as SMEs, large-companies etc), research organizations, higher education institutions, and other public organizations with R&D activities). Individuals as well as individual enterprises are not eligible under this scheme.  Applicants may submit, if they are enterprises, up to two (2) proposals from the same enterprise in the current call, and for Public research Institutes and Universities up to (2) proposals at the level of the same Laboratory or School or Institute or Department.   * ***Aid of intensity***   **Public research Institutes and Universities**: the aid intensity can reach 100% for performing non-economic activities in accordance with point 19, article 2.1.1 of the «Framework for State aid for research and development and innovation» (2014/C 198/01).  **Private Sector:** (a) 50% of the eligible costs for industrial research; (b) 25% of the eligible costs for experimental development; (c) 50% of the eligible costs for feasibility studies.- The aid intensities for industrial research and experimental development may be increased up to a maximum aid intensity of 80% of the eligible costs as follows:  (a) by 10 percentage points for medium-sized enterprises and by 20 percentage points for small enterprises;  (b) by 15 percentage points if one of the following conditions is fulfilled:  **(i)** the project involves effective collaboration:  **—** between undertakings among which at least one is an SME, or is carried out in at least two Member States, or in a Member State and in a Contracting Party of the EEA Agreement, and no single undertaking bears more than 70 % of the eligible costs, or  **—** between an undertaking and one or more research and knowledge-dissemination organisations, where the latter bear at least 10 % of the eligible costs and have the right to publish their own research results;  **(ii)** the results of the project are widely disseminated through conferences, publication, open access repositories, or free or open source software.  -The aid intensity for feasibility studies may be increased by 10 percentage points for medium-sized enterprises and by 20 percentage points for small enterprises.   * **Foreseen cost categories:**   (a) personnel costs: researchers, technicians and other supporting staff to the extent employed on the project.  (b) costs on fixed assets i.e. b1) costs of instruments and equipment to the extent and for the period used for the project. Where such instruments and equipment are not used for their full life for the project, only the depreciation costs corresponding to the life of the project, as calculated on the basis of generally accepted accounting principles are considered as eligible and b2) costs for buildings and land, to the extent and for the duration period used for the project. With regard to buildings, only the depreciation costs corresponding to the life of the project, as calculated on the basis of generally accepted accounting principles are considered as eligible. For land, costs of commercial transfer or actually incurred capital costs are eligible.  (c) costs of contractual research, knowledge and patents bought or licensed from outside sources at arm's length conditions, as well as costs of consultancy and equivalent services used exclusively for the project.  (d) additional general costs and other operating expenses, including costs of materials, supplies, travel expenses, organization of meetings, dissemination/publicity costs, audit costs, incurred directly as a result of the project implementation.  (e) indirect costs = flat rate 15% of gross personnel costs excluding VAT = 15%\* (a-(VAT of a)). Indirect costs are eligible for all legal entities and include costs that do not incur directly as a result of the project implementation (e. g. administrative and management costs, utility costs).   * **Upper funding limits for the eligible costs**   Upper limit of the total public funding will be 200.000 € per project (including indirect costs). Please note that this amount can be increased to 250.000 € per project if Greek partner assumes the project coordination. The maximum state aid intensity will be calculated according to the provisions of the European state aid rules and regulations in force (type of research activity, size of the participating enterprise, collaborative research). |
| Eligible costs as Indirect Costs | Indirect costs = flat rate 15% of gross personnel costs excluding VAT = 15%\* (a-(VAT of a)). Indirect costs are eligible for all legal entities and include costs that do not incur directly as a result of the project implementation (e. g. administrative and management costs, utility costs).   * **Note**: -Please bear in mind that scientific management costs are eligible under category (a) whereas administrative and financial/legal management costs fall under eligible categories (e) or (d)-audit costs only. |
| Maximum duration of projects | The duration of a funded project is 24-30 months. A possible extension of the duration under conditions can be accepted for the projects with a project duration of 24 months with a maximum up to the 1/3 of the initial duration taking into account the starting date without modifying the scientific or increasing the financial part of the project and the prerequisites of the current Operational Programme 2014-2020 (e.g. closing date for financing the projects in national level). |
| Further guidance | At national level, only eligibility check is conducted and not a full peer review at pre-proposals and full proposals stages. We rely on the evaluation made by the COFUND Call Evaluation Committee and external reviewers.  ***Submission at the national level is required at a later stage.*** A national call will be published to support the approved, at the transnational level, proposals only. Detailed information on the procedure and the funding rules will be provided at the GSRT website in the guidelines of the national call, during the submission period.  For more information please contact the NCP. |

ISRAEL

|  |  |
| --- | --- |
| **Funding organisation** | Chief Scientist office, Ministry of Health (CSO-MOH)  http://www.health.gov.il/ |
| **National contact person** | Dr. Irit Allon  **Phone:** +972 (0)2 5082167 ; **Email:** [irit.allon@moh.health.gov.il](mailto:irit.allon@moh.health.gov.il)  Chief Scientist Office, Ministry of Health  Orly Spivak  **Phone:** +972 (0) 526314326; **Email:** [orlee.f@gmail.com](mailto:orlee.f@gmail.com)  Chief Scientist Office, Ministry of Health |
| **Funding commitment** | Up to 240,000 €, depending on budget availability |
| **Anticipated number of fundable research groups** | Up to 2 projects |
| **Maximum funding per grant awarded to a partner** | Up to 140,000 €  Additional 20,000 € for coordination |
| **Eligibility of project duration** | Up to 3 years |
| **Eligibility of a partner as a beneficiary institution** | Position in a university, research center or hospital. Research authority must approve position prior to submission. |
| **Eligibility of principal investigator or other research team member** | PI should hold a Ph.D., M.D., D.M.D., D. Sc or equivalent degree and employed by an eligible institution. Research will not be funded simultaneously by CSO-MOH on more than one grant (Era-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any programme. |
| **Eligibility of costs, types and their caps** | Materials and consumables; Travel (up to 10%); No salaries for applicants; No heavy equipment,  Institutional overhead 10%. |
| **Submission of the proposal at the national level** | Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of abstract can result in declaration of the consortium as ineligible. |
| **Submission of other information at the national level** | If the application involves human or animal experiments, bioethics approvals must be submitted with the  application or up to 4 months later. |
| **Submission of financial and scientific reports at the national level** | Required annually. |
| **Further guidance** | Please see detailed instructions of application at the national level and reporting  at <http://www.health.gov.il/research-fund> |

ITALY

|  |  |
| --- | --- |
| Country | ITALY |
| Funding organisation | IMH - Ministry of Health ( [www.salute.gov.it](http://www.salute.gov.it) ) |
| National Contact Point for the 11TH call of EuroNanoMed | Directorate General for Health Research and Innovation  Ministry of Health – Ministero della Salute  Office 3  Viale Giorgio Ribotta, 5  00144 Rome, Italy  Email: [research.eu.dgric@sanita.it](mailto:research.eu.dgric@sanita.it); Phone: +39 06.5994. 3215  Maria Grazia Mancini (Email: mg.mancini-esterno@sanita.it ;[research.eu.dgric@sanita.it](mailto:research.eu.dgric@sanita.it)) |
| National programme | Framework of National Health Research Programme of the Ministry of Health |
| Funding commitment | 1.0 Mio. € |
| Anticipated number of fundable project partners | ~ 4 |
| Maximum funding per grant awarded to a project partner | ~ 0.25 M€ |
| Eligibility of projects duration | Up to 3 years |
| Eligibility of a partner as a beneficiary institution | * Fundable: ONLY IRCCS that are the Scientific Institutes for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati) and ISS (Istituto Superiore Sanità) [National Institute of Health and ISS] * Non fundable: University, research institute and other research institute   The simultaneous participation in proposals submitted in 2019 for different transnational research calls funded by the Ministry of Health is not allowed to Italian Principal Investigators, including WP leaders |
| Eligibility of costs, types and their caps | * Direct Costs:   Personnel (only temporary contracts) (max 50%);  Consumables;  Animals;  Equipment (only on hire);  Travel (max 10%):  Documentation (Max 1%)   * Indirect Costs:   Overhead (max 10%);   * Other indirect costs are not eligible |
| National phase | In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the proposals. To this end, it is mandatory that the applicants fill out and return a [pre-submission eligibility check](http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf) form through IRCCS Scientific Directorate using WFR System before submitting their proposals to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the proposal submission deadline. Applicants will be sent a written notification of their eligibility status. The simultaneous participation in proposals submitted in 2019 for different transnational research calls funded by the *Italian* *Ministry of Health* is not allowed to Italian Principal Investigators or other research team members. |
| Submission of financial and scientific reports at the national level | The mid-term and final scientific reports to the JCS are sufficient |
| Further guidance | After the ENMIII JTC 2020 peer review process has been completed and the final (scientific) ranking list has been established and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). Submission of annual scientific and financial reports at the national level will be required according to the rules of the Ministry of Health. Further information on the rules of the Ministry of Health can be found at [www.salute.gov.it](http://www.salute.gov.it/) or requested to the national contact persons. |

LATVIA

|  |  |
| --- | --- |
| Funding Organisation | State Education Development Agency [www.viaa.gov.lv](http://www.viaa.gov.lv) |
| Initial funding  pre-commitment | Latvian contribution to the call budget: 420.000 €.  Upper funding limit is 70 000 EUR/year per project participant. |
| National Contact Point for the 11TH call of EuroNanoMed | Dr.Linda Vecbiškena  Tel.: (+371) 25153082  Fax: (+371) 67814344  E-mail: [linda.vecbiskena@viaa.gov.lv](mailto:linda.vecbiskena@viaa.gov.lv)  State Education Development Agency  Vaļņu street 1, Riga, LV-1050  Latvia |
| Eligible institutions | Legal persons (as defined under the Latvian law) are eligible for funding, except natural persons:   * R&D institutions - research institutes, universities, higher education establishments, their institutes and research centres etc. * Enterprises and companies.   R&D institution (research institutes, universities, higher education establishments, research centres etc.) must be listed in the Registry of Research Institutions operated by the Ministry of Education and Science of the Republic of Latvia.  Private entities must be registered in the Registry of Enterprises of the Republic of Latvia and provide most of its R&D&I activities in the Republic of Latvia. |
| Additional eligibility criteria | Information will be available at the national call and national contact point. |
| Eligible costs | Eligible direct costs for Latvian researchers:   * Personnel * Subcontracting (up to 20% of total direct costs) * Consumables, materials * Travel and Subsistence * Equipment (only depreciation costs) * Other * Overheads: * Up to 25% of eligible direct cost excluding subcontracting costs. |

LITHUANIA

|  |  |
| --- | --- |
| Funding Organisation | Research Council of Lithuania [www.lmt.lt](http://www.lmt.lt) |
| Initial funding  pre-commitment | Lithuania’s contribution to the call budget: 100. 000 € - 150 000 €.  For one three years project Lithuanian participants can require up to 150 000 € as a coordinator or up to 100 000 € as a mere partner. |
| National Contact Point for the 11TH call of EuroNanoMed | Ms. Živilė Ruželė  Tel.: (+370) 5 236 0507  Fax: (+370) 5 261 8535  E-mail: [zivile.ruzele@lmt.lt](mailto:zivile.ruzele@lmt.lt)  Research Council of Lithuania  Gedimino Av.. 3, Vilnius  Lithuania |
| Eligible institutions | * Lithuanian research and education institutions: Universities, Research centres * Public health care institutions: University hospitals, other public hospitals. * SME (in collaboration with Lithuanian research and education institutions and health care institutions) meeting special criteria. More information will be available at the national call and national contact point. |
| Additional eligibility criteria | Information will be available at the national call and national contact point. |
| Eligible costs | Eligible direct costs for Lithuanian researchers:   * Personnel * Subcontracting * Consumables * Travel and Subsistence * Equipment * Other   Overheads:   * Up to 30% of Personnel and Subcontracting costs. |
| Further guidance | This is not a comprehensive list of requirements for the Lithuanian participants. All national rules are presented in the Lithuanian language in the call text and Rules for Funding ([Lietuvos mokslo tarybos mokslo ir sklaidos projektų konkursinio finansavimo bendrosios taisyklės](https://www.e-tar.lt/portal/lt/legalAct/ec3460a004fe11e8b3e7ba9cffd043b1/asr)). |

NORWAY

|  |  |
| --- | --- |
| Funding Organisation | Research Council of Norway |
| Initial funding  pre-commitment | Available amount of funding in total €: Up to 750 000 € over 3 years in the medical field of cancer.  Norwegian partners may seek funding in EUR corresponding to the following limitations: - maximum 300 k€ per partner if NOT coordinator of the whole EuroNanoMed project proposal - maximum 350 k€ per partner if coordinator of the whole EuroNanoMed project proposal - maximum 450 k€ per project if the project has TWO Norwegian partners, also applying the above given limits of € per partner.  - An industrial partner is funded with up to 40 % of their eligible project costs.  Tentative number of projects to be funded: 2-3 projects (2-3 partners)  Contracts are made in NOK and transitions to NOK is based on the currency exchange rate in effect on the proposal deadline date. |
| National Contact Point for the 11TH call of EuroNanoMed | Cecilie Anita Mathiesen,  Direct phone: + 47 22 03 75 43, Mobile phone: + 47 456 90 357  E-mail: [cam@rcn.no](mailto:cam@rcn.no)  The Research Council of Norway  P.O Box 564 N-1327 Lysaker, Norway , Visiting address: Drammensveien 288, 0283 Oslo |
| Eligible institutions | Norwegian Universities, University colleges, Institutes, Industry, and Public Sector. Industries are funded with up to 40 % of their eligible project costs. |
| Additional eligibility criteria | Norwegian funding the ENMIII JTC2020 shall only be applied to Norwegian research institutions or research active enterprises in the medical field of cancer. |
| Eligible costs | All the general national rules for funding and eligible costs (in short described below) apply, and here the overhead cost is included.  For researcher projects (only partner(s) from research institutions as Norwegian partner(s)):  Relevant project expenses such as payroll expenses, one or more grants/fellowships, procurement of R&D services, network measures, depreciation of equipment used under the project.  For innovation projects (only partner(s) from industry as Norwegian partner(s)):  Relevant project costs such as payroll expenses, procurement of external R&D services and one or more grants/fellowships and direct project expenses. Applications will be accepted from Companies, groups of companies or trade and industry organisations that have been officially issued an enterprise number under the Register of Business Enterprises. Any exceptions to this will be described in the call for proposals.  For Collaborative and Knowledge-building Project (partner(s) from research institutions and industry as Norwegian partner(s)):  Industry relevant project expenses incurred by the Project Owner and any other cooperating research institutions, including payroll expenses, one or more grants/fellowships and direct project expenses  Due to the budget size, the following limitations apply for fellowships: - A PhD fellowship CAN NOT be sought  - A postdoc fellowship can be minimum and maximum 2 years  Use this RCN national frames setting up the budget and transform it to the EuroNanoMed budget form (in this case the overhead budget line is set to 0,-). Use the euro exchange rate valid at this time. |

POLAND

|  |  |
| --- | --- |
| Funding Organisation | National Centre for Research and Development  [www.ncbr.gov.pl](file:///\\ANR-SRV-FILER01\Departements\0012-Biologie_Sante\Archivage_AAP_Biologie%20Sante\11_International\EuroNanoMed\EuroNanoMed%20III\AAP\JTC2017\call%20documents\guidelines\www.ncbr.gov.pl) |
| Initial funding  pre-commitment | 600.000 €  1-3 projects tentatively envisaged to be funded; one project can require up to 200 000 €. |
| National Contact Point for the 11TH call of EuroNanoMed | National Centre for Research and Development  Marcin Chmielewski  e-mail: [marcin.chmielewski@ncbr.gov.pl](mailto:marcin.chmielewski@ncbr.gov.pl)  phone: +48 22 39 07 109 |
| Eligible institutions | Following entities are eligible to apply:   * Micro, Small, Medium and Large Enterprise; Research organizations. |
| Additional eligibility criteria | **IMPORTANT: A project consortium with Polish participation must include at least one Polish enterprise.**  **In addition, if two Polish participants take part in the project, they must form an internal national consortium to sign the contract with the National Center for Research and Development (NCBR). The above consortium should be created on the day of signing the national agreement at the latest. The Polish consortium counts as two project partners from Poland (it meets the limit on the number of participants from the same country, please see call text for details).**  Organization must be registered in Poland.   * For enterprises it is strongly advised to state in the Pre-proposal application form in table for Project coordinator/Project partner, in the row “Other information”: the KRS number of the enterprise and the size of the enterprise (micro/small, medium, large). |
| Eligible costs | The eligible costs shall be the following:   1. Personnel costs (researchers, technicians and other supporting staff to the extent employed on the research project); 2. Costs of instruments and equipment, technical knowledge and patents to the extent and for the period used for the research project; if such instruments and equipment are not used for their full life for the research project, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice, shall be considered eligible; 3. Costs for buildings and land, to the extent and for the duration used for the research project; with regard to buildings, only the depreciation costs corresponding to the life of the research project, as calculated on the basis of good accounting practice shall be considered eligible; for land, costs of commercial transfer or actually incurred capital costs shall be eligible; 4. Cost of contractual research, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national experts panel; 5. Other operating costs including costs of materials, supplies and similar products incurred directly as a result of the research activity; 6. Additional overheads incurred indirectly as a result of the research project; that costs cannot account for more than 25% of all eligible project costs; That costs (6) are counted as a multiplication by percentage given above (called x%) and the rest of direct costs, excluding subcontracting (4); It means 6=(1+2+3+5)\*x%.   Funding quota of Polish participants can be up to 100% for universities or research organisations. In the case of enterprises, funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities and commercial perspective of exploitation.   |  |  |  |  |  | | --- | --- | --- | --- | --- | |  | **Large Enterprises** | **Medium Enterprises** | **Micro/Small Enterprises** | **Research organizations** | | **Fundamental/Basic Research** | **n/a** | **n/a** | **n/a** | **n/a** | | **Industrial/Applied Research** | **Up to**  **50+15 (max65%)** | **Up to**  **50+10+15 (max75%)** | **Up to**  **50+20+15 (max 80 %)** | **Up to**  **100 %** | | **Experimental development** | **Up to**  **25+15 (max40 %)** | **Up to**  **25+10+15 (max50%)** | **Up to**  **25+20+15 (max 60 %)** | **Up to**  **100 %** |   Only Applied Research and Experimental Development will be funded.  Other type of activities (e.g. coordination, dissemination, management) cannot be included into separated task.  All eligible entities, invited to submit Polish proposal are obliged to use the rate of exchange of The European Central Bank dated on the day of opening the call. |
| Further guidance | Applicants are advised that this annex is for general guidance only. For more detailed rules and regulations please refer to the national call announcement and contact the National Contact Point. |

ROMANIA

|  |  |
| --- | --- |
| Funding Organisation | Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI) <http://uefiscdi.gov.ro/> |
| Initial funding  pre-commitment | 500.000 euro  1-2 projects |
| National Contact Point for the 11TH call of EuroNanoMed | Mihaela Manole (+40) 21 3023863  [mihaela.manole@uefiscdi.ro](mailto:mihaela.manole@uefiscdi.ro)  UEFISCDI funding R & D projects, declared winner by participating in launched calls for ERANET projects – in Horizon 2020 Subprogramme |
| Eligibility criteria | Eligible entities for funding are universities, public institutions, R&D national institutions, joint-stock companies, SME’s and Large companies, NGOs (associations, foundations, etc.), others.  Funding rates vary in accordance with state aid legislation.  For more information : <https://www.uefiscdi.ro/pachet-de-informatii-suprogramul-3-2-orizont-2020>  Eligibility cost:  a. Staff costs;  b. Logistics expenses  - Capital expenditure ;  - Expenditure on stocks - supplies and inventory items;  - Expenditure on services performed by third parties cannot exceed 25 % of the funding from the public budget. The subcontracted parts should not be core/substantial parts of the project work;  c. Travel expenses;  d. Overhead (indirect costs) is calculated as a percentage of direct costs: staff costs, logistics costs (excluding capital costs and cost for subcontracting) and travel expenses. Indirect costs will not exceed 20 % of direct costs. |

SLOVAKIA

|  |  |
| --- | --- |
| Funding Organisation | Slovak Academy of Sciences (SAS)  <http://www.sav.sk/> |
| Initial funding  pre-commitment | Up to 120. 000 €  Anticipated number of funded projects: 1  Maximal annual budget per project is 40.000 € |
| National Contact Point for the 11TH call of EuroNanoMed | Katarina BIBOVA  e-mail : [bibova@up.upsav.sk](mailto:bibova@up.upsav.sk) , Phone : +421 2 5751 0136  Address: Slovak Academy of Sciences  Štefánikova 49  814 38 Bratislava  SLOVAKIA |
| Eligible institutions | Only research Institutes of Slovak Academy of Sciences are eligible organisations for funding (up to 100%). Applicants from other Slovak R&D centers have to cover the project costs from their own sources (Letter of Commitment). The teams outside of SAS (universities and/or another organisations) can be consortium members but not the coordinator of the consortium. |
| Additional eligibility criteria | Eligible costs as defined in the EuroNanoMed III Joint Transnational Call for Proposals 2020 text can be applied unless they are in conflict with the SAS Financial Rules for awarding grants for research projects. Priority is given to the SAS Financial Rules. <https://www.sav.sk/index.php?lang=sk&doc=services-news&source_no=25&news_no=7114> |
| Eligible costs | Direct costs (DC) : Personnel (max. of 15 % of all DC ( ERA.Nets) or max. of 30% of all DC, if Slovak team is a coordinator of consortium ), Consumables, Equipment (max. 40% of DC) and Travel costs  Indirect costs (IC - overheads): max. 20 % of DC. Total eligible costs = DC + IC  Training costs shall not be defined as a separate category, but included in other costs items. |
| Further guidance | National phase: Submission of the proposal at the national level will be required in parallel to the international evaluation. The submission will be carried out once the international evaluation and the ranking list have been performed and endorsed by the EuroNanoMed II Call Steering Committee (CSC) and the Slovak project partner has been informed by the project consortium coordinator and invited by SAS to submit the proposal to it (Formular MVTS). The Presidium of SAS makes the final decision for funding of selected projects.  ■ Web site: http://www.sav.sk/; ■ 133 Act of February 19, 2002 on the Slovak Academy of Sciences,  ■ Financial rules for awarding SAS grants for research projects in frame of ERA.Net  Programme for research institutes of SAS  <https://www.sav.sk/index.php?lang=sk&doc=services-news&source_no=25&news_no=7114>  ■ Principles of allocation of funds for the institutes of SAS to support projects in the field of  international scientific cooperation  For more information please contact the NCP |

SPAIN (CDTI)

|  |  |
| --- | --- |
| Funding Organisation | Centro para el Desarrollo Tecnológico Industrial, E.P.E. (CDTI)  <http://www.cdti.es> |
| Initial funding  pre-commitment | EUR 500,000 (\*)  3-5 projects tentatively envisaged to be funded |
| National  programme | 1. R+D+i Internationalisation Programme 2. <http://www.cdti.es/index.asp?MP=7&MS=563&MN=3> |
| National Contact Point for the 11TH call of EuroNanoMed | Héctor González  [hector.gonzalez@cdti.es](mailto:hector.gonzalez@cdti.es)  +34915810599 |
| Eligibility criteria | * Eligible entities: for-profit companies (being large or SME) established and carrying out R&D activities in Spain. Other entities such as universities, public research institutions, technological centres, and other private non-profit institutions could participate under subcontracting by Spanish companies (provided that, the entity or respective researcher is not requesting funding simultaneously from AEI-MINECO or ISCIII for the same activities).Eligible activities: technology-based industrial research and/or experimental development activities (in accordance with the definitions of EC Regulation nº651/2014), representing outstanding scientific-technical quality and high innovative potential. The Spanish part of the proposed work plan must be developed in Spain. Management and dissemination-related activities are explicitly excluded for funding. * Project duration: 12 to 36 months. * Project budget: The minimum eligible budget amounts to €175,000 per partner (this figure applies to the partner budget not the requesting funding). * Eligible costs: * Personnel (intended exclusively for the RTD activities within the project). * Instrument and equipment costs, to the extent and during the period in which they are used for the RTD activities of the research project. * Contractual research costs, technical knowledge and patents bought or licensed from outside sources at market prices, and costs for consulting and equivalent services intended exclusively for the research activity. * Other operating expenses, including costs for material, supplies and similar products, which result directly from the RTD activities of the research project; project audit (when applicable); Overheads.   Management & dissemination-related activities are not eligible for funding.  The detailed description is available on CDTI website:  <http://www.cdti.es/index.asp?MP=7&MS=724&MN=3&TR=C&IDR=2515>   * CDTI Funding: will be based on a financing package, entailing soft loans (up to 75% of the eligible budget, 85 % in exceptional cases) with a non-repayable part, up to 33 % of the loan. The available budget for the non-repayable part amounts to € 500,000. * *Specific financial conditions for ensuring the beneficiary’s solvency could be required according to CDTI funding rules. CDTI will avoid double funding, and will not finance projects, or parts of projects, that have been already funded through other national, transnational or EU calls. CDTI will be responsible for making the final decision regarding the awarding of funds to those Spanish applicants aiming to receive funding from CDTI, taking fully into account the assesment of the nationa full proposal, the transnational evaluation of the collaborative project, the previous funds received by the participants for other related projects, the fulfilment of eligibility and funding rules, and the financial resources available. Further information is available on:*     [*http://www.cdti.es/index.asp?MP=100&MS=802&MN=2&r=1920\*1080*](http://www.cdti.es/index.asp?MP=100&MS=802&MN=2&r=1920*1080)   * National application: applicants requesting funding from CDTI must submit a formal proposal via the CDTI electronic submission system (<https://sede.cdti.gob.es>). The proposal must include a detailed description, in Spanish Language, of the activities to be undertaken by the applicant and their respective budget. Further guidance will be published on CDTI website. Applicants must indicate their VAT (CIF) number in all their respective applications (both international and national).   Applicants are strongly advised to check the detailed information available on the CDTI website and to contact the NCP for getting advice about national funding rules before submitting a proposal. |

SPAIN (ISCIII)

|  |  |
| --- | --- |
| Funding Organisation | **National Institute of Health Carlos III (ISCIII)**  [www.isciii.es](http://www.isciii.es) |
| National Funding Programme | Acción Estratégica en Salud (AES 2020)  <http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml> |
| Initial funding  pre-commitment | 500.000 €  3-5 projects tentatively envisaged to be funded |
| National Contact Point for the 11th call of EuroNanoMed | Astrid Valencia  Email: ma.valencia@isciii.es  Tel: (+34) 91 822 2227 |
| Maximum funding per awarded Spanish project partner | * Up to **175.000** € per partner (overheads included) Up to **250.000** € per coordinator (overheads included)   **Additional 50.000 € could be granted if there is another industrial partner funded by CDTI in the consortium** (i.e. up to 225.000 € as partner, up to 300.000 € as coordinator) |
| Eligible institutions | * **Hospitals, primary health care settings or public health administration of the Spanish National Health System** (SNS)   These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation’s statutes may be submitted).   * **Accredited Health Research Institutes** (Institutos de Investigación Sanitaria acreditados, IIS)   Accredited according to the RD 339/2004, of February 27th or RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th) <http://www.eng.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-institutos-investigacion-sanitaria/listado-de-iis-acreditados.shtml>   * **CIBER or CIBERNED**   Team members applying to the call must be from at least 2 groups belonging to CIBER in **2 different home institutions** and one of these two should be a Hospital, primary health care setting or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS).   * **Academia or Other Research Centers.** These entities can **only** participate if they apply together with Hospitals, primary health care settings or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). It is not allowed to apply independently, thus **there must be two beneficiary Spanish institutions in the same proposal**.   **NOTE**:   * Applicants from ISCIII are allowed. * Same institution cannot participate with more than one partner in the same project proposal.   SMEs and other private companies are encouraged to participate at their own cost, as subcontractors or funded by CDTI. |
| Additional eligibility criteria | * Grants are awarded for a maximum of 3 years. * Due to administrative and legal regulations, the National Institute of Health Carlos III declares 30th of September 2020 as national deadline for the decision on fundable project consortia which include Spanish partners to be funded by ISCIII. Any concerned applicant in a proposal for which no final decision has been made by the deadline, could be declared not fundable by ISCIII.   **NOTE**: Researchers with ongoing EuroNanoMed projects in 2020 cannot apply to the current call unless the alive project or the new application is as coordinator. |
| Eligibility of PI and team members | * Principal Investigators (PI) can only participate in one project proposal per call * PI and all members of the research group must belong to the eligible institution or be affiliated to CIBER, CIBERNED or an IIS.   **Excluded** personnel as Principal Investigator (PI):  • Those undergoing a postgraduate training in Health Specialization (MIR, FIR, QIR, BIR, PIR)  • Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts)  • Researchers contracted by a RETIC or a CONSOLIDER  • Those undergoing postdoctoral training (e.g. “Sara Borrell“ or “Juan de la Cierva” contracts) |
| Eligible costs | Personnel costs for temporary employment contracts (scholarships are not eligible).  Current costs, small scientific equipment, consumables, disposable materials, traveling expenses and other costs than can be justified as necessary to carry out the proposed activities.  Overheads according to AES 2020. |
| National phase | * National applications will be required by ISCIII. National submission period will be published in the AES 2020 under the call for “International Joint Programming Projects” (Proyectos de Programación Conjunta Internacional). Spanish Applicants should periodically check the web page of ISCIII. ISCIII may not send invitations to the mandatory national phase. * ISCIII and AEI may exchange each other applicant (s) in order to maximize the available funds meeting the respective eligibility rules. |
| Mandatory acknowledgement | Any publication, data base, product or event protected with IPR or not, resulting from the granted project must acknowledge “*Award no. XX by ISCIII thorough AES 2020 and within the framework of EuroNanoMed”* even after the end of the project*.* |
| Requirements on data and repositories | * Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the “ELIXIR Core Data Resources" or if non-European repositories or data bases they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI). * ISCIII may no fund project that requires the construction of new repositories without decommissioning plans or ensured sustainability after the project´s end. |

SPAIN (AEI)

|  |  |
| --- | --- |
| Funding organisation | Ministry of Science, Innovation and Universities – through the State Research Agency |
| Funding programme | *Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016*. [*Enlace a Plan Estatal*](http://www.idi.mineco.gob.es/portal/site/MICINN/menuitem.d20caeda35a0c5dc7c68b11001432ea0/?vgnextoid=33f85656ecfee310VgnVCM1000001d04140aRCRD)  The instrument for funding the Spanish groups will be the Spanish Call on International Joint Programming Actions 2018 (*Acciones de Programación Conjunta Internacional 2018*) or its equivalent. Only as a reference, the beneficiaries are advised to read the call. [*APCIN 201*](http://www.idi.mineco.gob.es/portal/site/MICINN/menuitem.d20caeda35a0c5dc7c68b11001432ea0/?vgnextoid=33f85656ecfee310VgnVCM1000001d04140aRCRD)*7*  The Spanish legal entities granted are obliged by the regulations established in this APCIN call (or its equivalent) and by the funding limits specified below.  EuroNanoMed call will be managed by the [*Subdivisión de Programas Científico-Técnicos Transversales, Fortalecimiento y Excelencia*](http://www.idi.mineco.gob.es/portal/site/MICINN/menuitem.8ce192e94ba842bea3bc811001432ea0/?vgnextoid=702ab68c910c1410VgnVCM1000001d04140aRCRD&vgnextchannel=07f839f740db2410VgnVCM1000001d04140aRCRD). |
| Purpose of funding | The projects granted by the State Research Agency must be aligned with the main objectives described in the [*Programa Estatal*](http://www.idi.mineco.gob.es/portal/site/MICINN/menuitem.d20caeda35a0c5dc7c68b11001432ea0/?vgnextoid=33f85656ecfee310VgnVCM1000001d04140aRCRD). |
| Initial funding  pre-commitment | Maximum funding for the EuroNanoMed JTC 2020: 400.000 € |
| National Contact Point for the 11TH call of EuroNanoMed | Beatriz Gomez : [beatriz.gomez@aei.gob.es](mailto:beatriz.gomez@aei.gob.es)  Contact email: era-nano@aei.gob.es  Representative: PhD. Estrella Fernández García |
| Eligible institutions | The **eligible entities** for the State Research Agency funding are:  Non-profit research organizations according to the APCIN call 2018 or its equivalent *(Acciones de Programación Conjunta Internacional 2018 o su equivalente).*  **Spanish non-profit research organizations funded by MINECO – AEI must participate in cooperation with one for-profit company funded by the Centro para el Desarrollo Tecnológico Industrial, E.P.E. (CDTI) or one organization funded by National Institute of Health Carlos III (ISCIII) in this call.**  Important: Eligible entities for ISCIII will not be eligible for the State Research Agency funding. Please read the ISCIII Annex.  In the event of exhaustion of funds by one funding organization, ISCIII and the State Research Agency reserve the right to transfer the affected project to the funding organization with remaining funds.  Final rules on eligibility will be defined in the APCIN 2018 call (or its equivalent), to be published [here](http://www.idi.mineco.gob.es/portal/site/MICINN/menuitem.d20caeda35a0c5dc7c68b11001432ea0/?vgnextoid=33f85656ecfee310VgnVCM1000001d04140aRCRD) |
| Additional eligibility criteria | Mandatory:  Spanish Principal Investigators **must be** eligible according to the APCIN 2018 call or its equivalent and must have experience as investigators in projects funded by the *Plan Nacional I+D+i 2008-2011,* the *Plan Estatal I+D+i 2013-2016*, ERC Grants, European Framework Programmes or other relevant international programmes.  Incompatibilities: These must be taken into account when participating in different ERA-Nets or other international initiatives.  - Principal Investigators are not allowed to apply for funding in more than one proposal of this ERA-NET EuroNanoMed III call.  - Principal Investigators will not be allowed to apply for funding in more than one proposal in the APCIN 2018 call or its equivalent.  -Principal Investigators who obtained funding in the APCIN 2017 call are not allowed to apply neither in APCIN 2018 or its equivalent nor in this transnational EuroNanoMed III call.  - Principal Investigators have to remain unchanged between the pre-proposal stage, the full proposal stage, and the National APCIN 2018 call or its equivalent.  The State Research Agency will avoid double funding (overlapping with other EU or National funding), and will not grant projects or parts of projects already funded. |
| Eligible costs | - Personnel costs for temporary employment contracts (scholarships are not eligible).  - Current costs, small scientific equipment, disposable materials, travelling expenses and other costs that can be justified as necessary to carry out the proposed activities.  - Indirect costs (overheads) or clinical trials (proofs of concept, proofs of principle) are not eligible for funding in the APCIN call. |
| Funding rates (approx.) | The following funding limits are considered eligibility criteria. Proposals not respecting these limits can be declared ineligible.  The maximum amount of funding is 150,000 € per proposal and legal entity (additional 50,000 € if the Spanish group leader is the coordinator of the international consortium).  The final funding will take into account the transnational evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, the participation of the industrial sector and the financial resources available. |
| Further instructions | Any publication or dissemination activity resulting from the granted projects must acknowledge the State Research Agency funding: “Project (reference nº XX) funded by the State Research Agency through APCIN 2018 (or its equivalent)”. |

TAIWAN

|  |  |
| --- | --- |
| Funding Organisation | Ministry of Science and Technology (Taiwan); https://www.most.gov.tw/en/public |
| Initial funding  pre-commitment | 500.000 €  Anticipated number of funded research groups: 3-4 |
| National Contact Point for the 11th call of EuroNanoMed | Ching-Mei Tang  E-Mail: [cmtom@most.gov.tw](mailto:cmtom@most.gov.tw)  Phone: +886-2-2737-7557 |
| Eligible institutions | All research institutes, universities, hospitals, public organisations in Taiwan endorsed by the Ministry of Science and Technology as beneficiary institution. |
| Additional eligibility criteria | The standard funding policy and eligibility rules set by the Ministry of Science and Technology applied. |
| Eligible costs | Personnel, Consumables, Hosting expenses for foreign researchers,  Travel expenses for international destinations-joint research |
| Further guidance | No official national application is needed in the pre-proposal or full proposal phase. But must notify the national contact person in the Ministry of Science and Technology of your submission to the joint transnational call via email, together with your application as an attachment.  For details of national application procedure, please refer to the joint-call announcement on the MOST’s website  <https://www.most.gov.tw/ch/academic> for more information. |

TURKEY

|  |  |
| --- | --- |
| Funding Organisation | The Scientific and Technological Research Council of Turkey (TUBITAK)  [www.tubitak.gov.tr](http://www.tubitak.gov.tr) |
| National Funding Programme | ARDEB 1071 - Support Programme for Increasing Capacity to Benefit from International Research Funds and Participation in International R&D Cooperation  <https://www.tubitak.gov.tr/sites/default/files/3125/ar-ge_ve_yenilik_bilgi_notu.pdf>  **Purpose:** development of new knowledge, solution to technological problems with scientific interpretations, improving/advancing current situation on the project topic, improving international cooperation.  Projects in which partner from Turkey is only responsible for demonstration actions cannot be supported by TUBITAK. |
| Initial funding  pre-commitment | Initial funding pre-commitment: **750.000 €**  **3-5 projects** tentatively envisaged to be funded.  ------------------------------------------------------------------------------------------------------------------  If there is more than one Turkish partner in a single transnational project, these partners should submit joint national application under TUBITAK 1071 programme via project application system of TUBITAK.  Maximum funding cannot exceed **1.500.000 TL** for each project (regardless of the number of the partners).  For each partner:  The maximum funding cannot exceed **720.000 TL** for Universities (public and private), research institutes, and public institutions.  The maximum funding cannot exceed **1.000.000 TL** for private corporations.  These amounts exclude payments to the PI, Co-PIs and overhead costs.  Percentage of Funding:  **Universities (public and private), research institutes and public institutions:** %100 of budget of the project will be funded by TUBITAK.  **Large-size Enterprises:** %60 of budget of the project will be funded by TUBITAK.  **Small and Medium-size Enterprises:** %75 of budget of the project will be funded by TUBITAK.  **For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
| National Contact Point for the 11th call of EuroNanoMed | Alperen Erdoğan  E-mail: [alperen.erdogan@tubitak.gov.tr](mailto:alperen.erdogan@tubitak.gov.tr)  Tel: (+90) 312 298 12 70  **Applicants are strongly recommended to reach the national contact point during the all application process.** |
| Eligible institutions | Applicants can apply from universities (public and private), research institutes, public and private corporations  **For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
| Eligibility of PI and team members | Principal Investigator\*, Researchers and Advisors:   * University personnel should have a PhD degree, * Those working in a public institution or a private corporation should have an undergraduate diploma, * The Principal Investigator (PI) should be the permanent staff of the organization making the project proposal, * The PI, researchers (Co-PI) and advisors should reside and work in Turkey (Foreign nationals can be PI/researcher in the projects if they are working in an organization in Turkey), * A researcher should have a contribution of at least 10% of the project workload, * An advisor is allowed if the project requires special expertise on a specific subject. The number of advisors in a project is limited to the number of specific subjects in the project. The role of advisor in the projects should be explained in detail in the project proposal.   \*University presidents and vice presidents, surgeon generals, vice surgeon generals, hospital presidents, institution/company presidents, and institution/company vice presidents are not allowed to be PI.  **For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
| Eligible costs | Eligible types of funding under this programme are limited to personnel costs, travel and subsistence, equipment, consumables and subcontracting/services. Projects intended to build infrastructure cannot be supported.  **For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
| Maximum duration of projects | 36 months |
| National phase | Project coordinator of consortium must send English application form to call secretariat via online application tool. At the same time, project coordinator of Turkish team in the consortium must apply 1st stage via project application system by using Turkish application form available on project application system of TUBITAK. If the Turkish team is invited for the 2nd stage, same procedure is supposed to be followed by project coordinator of the Turkish team, except using Turkish application form (for the 2nd stage, international application form should be submitted to the project application system)  **For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
| Other Important Issues | * Project coordinator, researchers and advisors must be registered to “Researcher Information System (ARBİS)” and their info must be updated. * Field studies in abroad cannot be supported. * There should not be any running or concluded projects of research team with similar content of the proposed project. * If works defined in proposal requires ethical committee certificate or legal/private permission, these permission documents in required format must be sent with second stage application to TUBITAK. * Any publication resulting from the granted projects must acknowledge TUBITAK fundingeven after the end of the project. * **For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.** |
| Further guidance | In addition to the national funding regulations provided herewith, all Turkish applicants are strongly recommended to check the announcements regarding this call under the official website of TUBITAK for the conditions of funding, and they are strongly advised to reach the Turkish national contact person before the application. |

Annex 3: Technology readiness levels (TRL)

* TRL 1 – basic principles observed
* TRL 2 – technology concept formulated
* TRL 3 – experimental proof of concept
* TRL 4 – technology validated in lab
* TRL 5 – technology validated in relevant environment (industrially relevant environment in the case of key enabling technologies)
* TRL 6 – technology demonstrated in relevant environment (industrially relevant environment in the case of key enabling technologies)
* TRL 7 – system prototype demonstration in operational environment
* TRL 8 – system complete and qualified
* TRL 9 – actual system proven in operational environment (competitive manufacturing in the case of key enabling technologies; or in space)

Annex 4: Guidelines for Responsible Research and Innovation (RRI) in proposals to EuroNanoMed III

**This RRI guideline is to give a short introduction to RRI as concept and provide sources for more information. It also presents *one possible way* of thinking about RRI and introducing these reflections and RRI measures into a project proposal in nanomedicine.**

Two key objectives for the ERA-NET for nanomedicine (EuroNanoMed III) are to:

1. Encourage the nanomedicine community to adopt RRI, HSE and ensure alignment with current regulatory requirements.
2. Train funded researchers on:
   * Translation processes ([NOBEL- PROJECT](https://nobel-project.eu) might be helpful here)
   * Responsible Research and Innovation (RRI), including co-creation, co-design and co-production
   * Regulatory aspects

**What is RRI?**

In a nutshell​ RRI is:

* Involving societal actors in science and innovation throughout R&I processes to better-align their orientation with the values of society.
* In Horizon 2020, RRI is described as a broad umbrella connecting different aspects of the relationship between R&I and society: public engagement, open access, gender equality, science education, ethics, and governance.

In the EU Programme for Research and Innovation 2014-2020, Horizon2020, **RRI is** **a cross-cutting issue**, actions are also promoted via ‘Science with and for Society’. Here is the [H2020 definition](http://ec.europa.eu/programmes/horizon2020/en/h2020-section/responsible-research-innovation) of RRI, including [public engagement](http://ec.europa.eu/programmes/horizon2020/en/h2020-section/public-engagement-responsible-research-and-innovation), [open access](http://ec.europa.eu/programmes/horizon2020/en/h2020-section/open-science-open-access), [gender](http://ec.europa.eu/programmes/horizon2020/en/h2020-section/promoting-gender-equality-research-and-innovation), [ethics](http://ec.europa.eu/programmes/horizon2020/en/h2020-section/ethics), [science education](http://ec.europa.eu/programmes/horizon2020/en/h2020-section/science-education).

More recently, RRI has been articulated as **co-creation, co-design and co-production**: methodologies in which projects are structured to include stakeholders from the outside (e.g. users or interest groups) with the expertise of the social sciences and humanities (SSH). This [RRI Movie](http://www.rri-tools.eu/) by RRI Tools describes the idea well also includes a broad RRI-toolbox.

**ENM’s Joint Transnational Call 2020 call text says the following:**  
"Projects are required to discuss and respond to [**Responsible Research and Innovation (RRI) aspects**](http://ec.europa.eu/programmes/horizon2020/en/h2020-section/responsible-research-innovation), **including co-creating, co-design and co-production**. Projects are required to include a plan to **disseminate results/outcomes** and how to achieve higher levels of technological readiness."

**How can you include RRI in your proposal?**

ENMIII’s philosophy is to have *RRI as an integrated part of the project* involving all project participants. This means that the approach taken should be specific to the project. While RRI may focus on broadly recognised issues, they should not be approached in a generic way.

Developing a *shared understanding of the project’s RRI aspects* as early as possible is really important. This will mean having conversations about their importance, action that is agreed upon, and what learning and adoption can occur throughout the project.

How this RRI content is adopted (e.g. who will be responsible for what work) in the proposal is project dependent. For example, RRI can be organised a cross-cutting part of the project or a separate work package. RRI in the project needs to be *coordinated*.

*Please be aware that these guidelines and reflections neither represent the only RRI approach nor a complete list of examples of measures when implementing RRI in nanomedicine proposals. If you are aware of other tools or infrastructures relevant for RRI implementation in research and innovation projects in nanomedicine, please inform cam[at]rcn.no.*

**The following list provides examples of different RRI perspectives applicable for nanomedicine research projects (including ethical and safety issues).** Choose those points relevant for your project.

1. Involve **stakeholders** of relevance to the project (e.g. clinicians, patient interest groups) at the earliest possible stage, to **pursue co-creation, co-design and co-production methodologies.**
   1. Co-design methodologies are important to generate trust but these stakeholders may also have knowledge about the social, environmental or commercial problem you are trying to address in your project.
   2. Think also about the appropriate **timing** of different stakeholders’ inclusion: certain kinds of knowledge may be more useful than others at different points of your project. (e.g. Doctors, physicians and patient groups early in the process with industry and investors at a later stage.)
   3. Think about **how** the involvement of these stakeholders and their knowledge can be formalised within your project. This may include a specific point in the middle of your project for reflection to occur, which may require your project to briefly pause, integrate this knowledge and potentially change course.
   4. It will likely be valuable (but not obligatory) to include **expertise beyond the natural and physical sciences** – such as social scientists, anthropologists or philosophers. They will be able to provide methodologies to address key challenges, such as the risk of hype and expectations of patients wanting treatment.
2. Involve all partners and participants **in ongoing consideration of RRI throughout the project period**. Remember to **disseminate results/outcomes** and publish via **open science channels** if possible. Involve RRI experts in project implementation, if appropriate.
3. Reflect on/consider adapting **your choice of research methods** regarding, for example:

* ethical issues,
* *in vivo*/*in vitro* experiments,
* use of new approaches such as “Safer by Design”.
* Are there ways that your project can advance common practices on these issues?

1. Address **environmental impacts and sustainable solutions** by including, for example:

* lifecycle analysis,
* ecotoxicology studies,
* nanocharacterisation at the European Nanomedicine Characterisation Laboratory ([EU-NCL](http://www.euncl.eu/)).

1. Show how the project (and product) **satisfy requirements for production safety and efficiency** by, for example:

* addressing health, safety and environment (HSE) issues;
  + - using the competence achieved by the [BIORIMA](https://www.biorima.eu/) project that aims to develop an Integrated Risk Management (IRM) framework for (nano)biomaterials (NBM) used in Advanced therapy medicinal products (ATMP) and Medical device (MD);
    - using the [EU NanoSafety Cluster](http://www.nanosafetycluster.eu/)
    - using the resources and knowledge from former pilot lines in your project, when relevant:
      * [NanoPilot](http://www.nanopilot.eu/homepage) – A pilot plant for the production of polymer-based nanopharmaceuticals in compliance with good manufacturing practice (GMP) (finished);
      * [Nanofacturing](http://nanofacturing.eu/) – A multiple-scale, manufacturing platform to support the extensive pipeline of nanopharmaceutical products being developed in Europe (finished);

1. Ensure that themedicine or device in the body **is a safe product with clear benefits for the patient** by, for example
   * listening to/satisfying user needs and safety concerns,
   * involving [regulatory affairs](https://en.wikipedia.org/wiki/Regulatory_affairs) professionals (toxicity tests, etc.),
   * communicating with regulatory entities (the [Food and Drug Administration](https://en.wikipedia.org/wiki/Food_and_Drug_Administration) (FDA) or the [European Medicines Agency](https://en.wikipedia.org/wiki/European_Medicines_Agency) (pharmaceuticals and medical devices), etc.
2. **Consider who will benefit and how these benefits can be delivered**
   * Does your project address a specific problem or need?
   * Does your framing of the problem fit with other people’s understanding of it? Can you gain access to these alternative framings?
   * In addition to societal benefits, also consider benefits to the research community through the generation of knowledge, access to infrastructure, the creation of networks and funding.
   * Consider the appropriate form of intellectual property in your project. Is it possible to adopt looser property rights than normal to broaden access? (See, e.g. the Open MTA.)
   * Could commercial or non-commercial organisations benefit from your research? How?
   * Consider also the risks and ways that these can be ameliorated. For instance, what are the risks of potential risks of data being released? How can you take care to ensure these data are interpreted appropriately?

**Do these reflections and include measures as early as possible to design the project as relevant (for society) as possible. This can avoid the project to end in a blind road or having to start over again almost from scratch.**

**All these points can also be relevant to discuss in the light of the** [**UN Sustainable Development Goals (SDG)**](https://www.un.org/sustainabledevelopment/sustainable-development-goals/)**.**